CASWELL FILE
4-16-81

MEMORANDUM

Date: April 16, 1981

Subject: EPA File Symbol: 1021-RULI ESBIOL INTERMEDIATE 2266
Caswell # 25

From: Cheryl A. Peterson
IRB/TSS

To: Mr. Franklin D. R. Gee
Product Manager (17)

Applicant: McLaughlin Gormley King Co.
8810 Tenth Ave. North
Minneapolis, MN 55427

Active Ingredients:

S-bioallethrin (d-trans-chrysanthemum monocarboxylic acid ester of d-2-allyl-4-hydroxy-3-methyl-2-cyclopenten-1-one)	2.628%
Other isomers	0.025%
Piperonyl butoxide technical	5.667%
-N-octyl bicycloheptene dicarboximide	9.467%
Chlorpyrifos (o,o-diethyl o0(3,5,6-trichloro 2-pyridyl)phosphorothioate)	28.331%
Aromatic Petroleum Distillate	15.843%
Petroleum Distillate	9.212%
Inert Ingredients	28.597%

Background:

This product is intended for formulation use only. The company has submitted an application for conditional registration of a new product. The "cite-all" method of support has been indicated, and no data have been submitted.

Recommendations:

IRB/TSS would have no objection on the basis of acute toxicological considerations to the conditional registration of the above product for formulating use only under the "cite-all" method of support with the labeling revisions indicated below.

Labeling:

1. The appropriate signal word is WARNING, as indicated by the applicant.

2. The PRACTICAL TREATMENT statements are acceptable with the following changes:

> IF SWALLOWED: Drink glass of water. Get immediate medical attention. Do not give anything by mouth to an unconscious person. It is preferrable to induce vomiting under medical supervision, otherwise induce vomiting by touching finger to back of throat.
>
> NOTE TO PHYSICIAN: This product contains a cholinesterase inhibitor. Atropine is antidotal. Aspiration hazard may exist with this product.

Page _____ is not included in this copy.

Pages 3 through 4 are not included in this copy.

The material not included contains the following type of information:

_____ Identity of product inert ingredients.

_____ Identity of product impurities.

_____ Description of the product manufacturing process.

_____ Description of quality control procedures.

_____ Identity of the source of product ingredients.

_____ Sales or other commercial/financial information.

X A draft product label.

_____ The product confidential statement of formula.

_____ Information about a pending registration action.

_____ FIFRA registration data.

_____ The document is a duplicate of page(s) _____.

_____ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.